----item----
version: 1
id: {F6625D77-42F0-44A5-B1C6-B00A964C3917}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/10/23/PharmAsia News Business Bulletin
parent: {3C066B44-2408-4C2D-939F-7AF55362398E}
name: PharmAsia News Business Bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 5bc26edc-5058-486a-a75f-bae3433a32f7

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{3B33748A-17E9-4241-8447-989BB3484DFB}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 6459

<p>A new regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p><p>Full stories can be accessed by clicking on the story title (subscription required).</p><p><p><a href="http://#https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/29/china-slump-hits-gsks-emerging-markets-business" target="_new">China Slump Hits GSK's Emerging Markets Business</a></p><p>GSK's emerging markets sales have again been hit by rising competition and the ongoing restructuring of its China business, but CEO Witty sees the dip as "reasonably temporary" and expects improvements in the fourth quarter.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/28/currencies-hit-lillys-emerging-market-sales-but-japan-brighter" target="_new">Currencies Hit Lilly's Emerging Market Sales But Japan Brighter</a></p><p>Chinese government moves to cut drug costs are further squeezing pharma multinationals including Lilly, which was also hit hard by currency effects in its emerging markets business last quarter. But the US firm's outlook in Japan seems brighter, based on new oncology developments.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/28/alcon-hits-novartiss-emerging-markets-performance" target="_new">Alcon Drags Down Novartis's Emerging Markets Performance</a></p><p>Novartis's performance in emerging markets slowed in the third quarter, due mainly to a slowdown in Asia and the sluggish results of Alcon, which was hit by weaker surgical equipment sales in the sector. Alcon is aiming to turn things around with revitalized leadership and a growth acceleration plan.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/26/roche-sees-continued-emerging-markets-strength-despite-slowdown" target="_new">Roche Sees Continued Emerging Markets Strength Despite Slowdown</a></p><p>As it reported a generally strong third quarter, Roche has said it foresees continued strength in China and other emerging markets, driven by the value of its products and despite a general growth slowdown over the past year.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/30/emerging-markets-turmoil-hits-bayers-consumer-health-business" target="_new">Emerging Markets Turmoil Hits Bayer's Consumer Health Business</a></p><p>Bayer has reported slower emerging market sales growth in its consumer health business due to an exposure to the overall geopolitical and macroeconomic situations in Russia and China, also being experienced by its competitors, but the German company assured investors that there is &ldquo;nothing wrong with&rdquo; its underlying business performance and perspective on long-term growth potential.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/30/sanofi-bolstered-by-china-broad-market-expansion-strategy" target="_new">Sanofi Bolstered By China 'Broad Market' Expansion Strategy</a></p><p>Amid an increasingly gloomy economic outlook for emerging markets as a whole, and China in particular, Sanofi delivered jaw-dropping 33% growth in China in the last quarter. Aggressive expansion into the country's vast low-tier market has started bearing fruit, said the company.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/28/acquisitions-help-strides-back-into-black" target="_new">Acquisitions Help Strides Back Into Black</a></p><p>Indian drug maker Strides Arcolab, which is aiming to build a global business-to-customer operation driven by its own product pipeline, swung to a net profit in the second financial quarter from a year ago, propelled by strong across-the-board sales momentum following a string of acquisitions. It is now looking at "very good growth from its combined assets."</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/25/partnerships-critical-to-building-chinas-rampd-ecosystem-pt1" target="_new">Partnerships Critical To Building China's R&D Ecosystem (Pt.1)</a></p><p>China has outlined the main goals for its 13th Five-Year Plan, under which the pharmaceutical sector is seen moving in the direction of increased innovation, and the government seems set to bring biologic medicine development to a new strategic level. But building a healthy ecosystem for drug development will require strong collaboration between multinational pharmaceutical companies and their domestic peers, MNCs told a recent forum in Shanghai.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/28/partnerships-critical-to-building-chinas-rampd-ecosystem-pt2" target="_new">Partnerships Critical To Building China's R&D Ecosystem (Pt.2)</a></p><p>Foreign pharmaceutical companies often have to wait years to bring new drugs to China due to the country's lengthy approval process, and are expressing concerns that such regulatory delays could push back by several years plans to introduce their latest drugs.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/26/beigene-pursues-divergent-strategy-in-seeking-$100m-us-ipo" target="_new">BeiGene Takes Different Path In Seeking $100m US IPO</a></p><p>Two well recognized Chinese biopharma companies, BeiGene and Hutchison China MediTech, have recently filed for initial public offerings of American Depositary Shares on the US Nasdaq market, with the aim of becoming integrated companies able to tap global markets. Both see good reasons for pursuing a path different to other Chinese peers that have recently delisted in the US.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/26/korean-stem-cell-ventures-pursuing-divergent-rampd-strategies" target="_new">Korean Stem Cell Ventures Pursuing Divergent R&D Strategies</a></p><p>Two South Korean stem cell therapy ventures, Corestem and CHA Biotech, are taking divergent strategies in R&D and commercialization, one pushing ahead with the rapid launch of its first product and the other taking time to optimize its pipeline. During a recent stem cell industry investor relations session in Seoul, the companies unveiled the thinking behind their pipeline progress and business strategies.</p><p><p>www.pharmasianews.com</p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 229

<p>A new regular roundup of commercial stories appearing in Scrip's sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151023T200001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151023T200001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151023T200001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC030202
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

361218
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042515Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

5bc26edc-5058-486a-a75f-bae3433a32f7
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042515Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
